VIR BIOTECHN.INC.DL-,0001

Vir Biotechnology stock hit a 52-week high of $11.66 and is currently trading at $11.70, implying a market capitalization of about $1.97 billion. Year-to-date return stands at 81% and the 12-month change at 129.2%. In Q2 2026, cash and cash equivalents rose to roughly $1.01 billion, driven by a large collaboration payment from Astellas, and Vir reported net income of $80.1 million after a loss in the year-ago period. H.C. Wainwright reiterates a buy rating with a $20.00 price target and notes fully recruited phase-3 programs for hepatitis D with topline data expected end of 2026/early 2027. » More on de.investing.com

Vir reported a net profit of $80.1 million for Q2, supported by license and collaboration revenues of $238.9 million, mainly from an upfront payment by Astellas, which raised cash and equivalents to about $1.01 billion. Phase II data for the hepatitis delta program showed an 88% “target-not-detected” rate at week 96, and recruitment for the ECLIPSE Phase III trials is complete. The stock rose more than 10% in after-hours trading; management sees financial runway into the second half of 2028 and expects top-line data from ECLIPSE 1 at the end of 2026 and from ECLIPSE 2 and 3 in early 2027. » More on de.investing.com

Vir Biotechnology confirmed the resignation of CFO Jason O’Byrne; Brent Sabatini was named interim chief financial officer. O’Byrne’s exit was not due to disagreements with the company, which has already begun the search for a successor. Investors were unsettled ahead of the quarterly report on July 30, and the stock fell intraday by about 7% to $8.68. The departure follows the resignation of the chief medical officer in April and heightens concerns about leadership continuity, capital allocation and clinical priorities. » More on de.investing.com